MATTHEW PHILIP GOETZ

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN, 55905, USA
    Breast Cancer Res Treat 101:113-21. 2007
  2. ncbi CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
    Matthew P Goetz
    Authors Affiliations Departments of Oncology, Biostatistics, Molecular Pharmacology and Experimental Therapeutics, and Pathology, Mayo Clinic, Rochester, Minnesota Departments of Surgery, Internal Medicine, and Pathology, Medical University of Vienna, Vienna Medical Department with Hematology and Medical Oncology and Institute of Pathology, Paracelsus Private Medical University, Salzburg and Departments of Internal Medicine and Pathology, Medical Hospital Feldkirch, Austria
    Clin Cancer Res 19:500-7. 2013
  3. ncbi Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1stStreet SW, Rochester, MN 55905, USA
    Breast Cancer Res 13:R27. 2011
  4. ncbi CYP2D6 genotype and tamoxifen response
    James M Rae
    Breast Cancer Res 7:E6. 2005
  5. ncbi A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Cancer Res 12:2080-7. 2006
  6. ncbi Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 23:9312-8. 2005
  7. ncbi Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response
    M P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Pharmacol Ther 83:160-6. 2008
  8. ncbi Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:5864-8. 2008
  9. ncbi Developments in combination chemotherapy for colorectal cancer
    Matthew P Goetz
    Mayo Clinic College of Medicine, Department of Oncology, 200 First Street Southwest, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 4:627-37. 2004
  10. ncbi Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials
    Matthew P Goetz
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 17:6944-51. 2011

Research Grants

  1. Tamoxifen biotransformation pathway pharmacogenomics
    Matthew Goetz; Fiscal Year: 2009
  2. Tamoxifen biotransformation pathway pharmacogenomics
    MATTHEW PHILIP GOETZ; Fiscal Year: 2010

Detail Information

Publications37

  1. ncbi The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN, 55905, USA
    Breast Cancer Res Treat 101:113-21. 2007
    ....
  2. ncbi CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
    Matthew P Goetz
    Authors Affiliations Departments of Oncology, Biostatistics, Molecular Pharmacology and Experimental Therapeutics, and Pathology, Mayo Clinic, Rochester, Minnesota Departments of Surgery, Internal Medicine, and Pathology, Medical University of Vienna, Vienna Medical Department with Hematology and Medical Oncology and Institute of Pathology, Paracelsus Private Medical University, Salzburg and Departments of Internal Medicine and Pathology, Medical Hospital Feldkirch, Austria
    Clin Cancer Res 19:500-7. 2013
    ..Controversy exists about CYP2D6 genotype and tamoxifen efficacy...
  3. ncbi Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 1stStreet SW, Rochester, MN 55905, USA
    Breast Cancer Res 13:R27. 2011
    ..Here, we characterize the molecular actions of endoxifen in breast cancer cells expressing ERĪ² and examine its effectiveness as an anti-estrogenic agent in these cell lines...
  4. ncbi CYP2D6 genotype and tamoxifen response
    James M Rae
    Breast Cancer Res 7:E6. 2005
  5. ncbi A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Cancer Res 12:2080-7. 2006
    ..In the adjuvant treatment of estrogen receptor (ER)-positive breast cancer, additional markers are needed to identify women at high risk for recurrence...
  6. ncbi Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 23:9312-8. 2005
    ..Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown...
  7. ncbi Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response
    M P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Pharmacol Ther 83:160-6. 2008
    ..The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized...
  8. ncbi Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance
    Matthew P Goetz
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:5864-8. 2008
    ..We sought to determine the combined effect of inherited (CYP2D6) and somatic (HOXB13/IL17BR) gene variation in tamoxifen-treated breast cancer...
  9. ncbi Developments in combination chemotherapy for colorectal cancer
    Matthew P Goetz
    Mayo Clinic College of Medicine, Department of Oncology, 200 First Street Southwest, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 4:627-37. 2004
    ..Further adjuvant studies are testing the benefit of the addition of biologic therapies to oxaliplatin and irinotecan-based combination chemotherapy...
  10. ncbi Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials
    Matthew P Goetz
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 17:6944-51. 2011
    ..Controversy exists regarding the association between CYP2D6 enzyme activity and tamoxifen effectiveness in the adjuvant treatment of invasive breast cancer; however, this association in the primary prevention of breast cancer is unknown...
  11. ncbi Coprescription of tamoxifen and medications that inhibit CYP2D6
    Kostandinos Sideras
    Department of Oncology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA
    J Clin Oncol 28:2768-76. 2010
    ....
  12. ncbi Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
    Matthew P Goetz
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Oncol 23:1078-87. 2005
    ..17-AAG induced Hsp70 in PBMCs, indicating that Hsp90 has been affected. Further evaluation of 17-AAG is ongoing using a twice-weekly regimen, and this schedule of 17-AAG is being tested in combination with chemotherapy...
  13. ncbi A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis
    Sandhya Pruthi
    Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:999-1012. 2007
    ....
  14. ncbi Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:572-7. 2007
    ..A phase I trial was performed to establish the maximum tolerated dose (MTD) of pemetrexed and oxaliplatin when B(12) and folate supplementation is used...
  15. ncbi Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    James N Ingle
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4674-82. 2010
    ....
  16. ncbi A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations
    Sandhya Pruthi
    Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1131-40. 2007
    ..The goal of this article is to provide clinicians who care for women with breast cancer a multidisciplinary, state-of-the art approach to the treatment of these patients...
  17. ncbi Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer
    James N Ingle
    Division of Medical Oncology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:3278-86. 2010
    ..These findings may have implications with regard to efficacy and adverse events and may indicate the need to "individualize" therapy with this drug...
  18. ncbi Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    Robert R McWilliams
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:516-21. 2007
    ..A combination regimen using all 4 agents could potentially increase response rates in CRC...
  19. ncbi Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis
    Matthew R Callstrom
    Department of Diagnostic Radiology, Oncology, Biostatistics, and Anesthesiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 241:572-80. 2006
    ....
  20. ncbi Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
    Matthew P Goetz
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:3761-9. 2003
    ..Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics...
  21. ncbi Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52
    James N Ingle
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Breast Cancer Res Treat 98:217-22. 2006
    ....
  22. ncbi Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem
    Matthew R Callstrom
    Department of Radiology, Mayo Clinic, Rochester, MN, USA
    Skeletal Radiol 35:1-15. 2006
    ....
  23. ncbi Oxaliplatin plus oral fluoropyrimidines in colorectal cancer
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 4:S37-42. 2004
    ..This review will detail the results of these trials focused on capecitabine-based combinations...
  24. ncbi Clinical trial designs for prospective validation of biomarkers
    Sumithra J Mandrekar
    Division of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA
    Am J Pharmacogenomics 5:317-25. 2005
    ..Additional research is clearly warranted to achieve the goal of 'predictive oncology'...
  25. ncbi Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation
    Matthew R Callstrom
    Department of Radiology, Mayo Clinic, 200 First St SW, E2, Rochester, MN 55905, USA
    Radiology 224:87-97. 2002
    ..Eight of 10 patients using analgesics reported reduced use at some time after RF ablation. No serious complications were observed. CONCLUSION: RF ablation of painful osteolytic metastases is safe, and the relief of pain is substantial...
  26. ncbi Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging
    Rajini Katipamula
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:4082-8. 2009
    ..We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN...
  27. ncbi The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells
    Xianglin Wu
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 69:1722-7. 2009
    ..These results support the theory that endoxifen is the primary metabolite responsible for the overall effectiveness of tamoxifen in the treatment of ER-positive breast cancer...
  28. ncbi Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
    Judith A Gilbert
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 7:944-51. 2008
    ....
  29. ncbi Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study
    Matthew P Goetz
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 22:300-6. 2004
    ..CONCLUSION: RFA of painful osteolytic metastases provides significant pain relief for cancer patients who have failed standard treatments...
  30. ncbi Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells
    Kathryn E Reinicke
    Department of Oncology, Mayo Clinic, Rochester, MN, 55905, USA
    Cancer Chemother Pharmacol 66:575-83. 2010
    ..In anticipation of combination regimens, interactions between aminoflavone and several anticancer drugs were investigated in MCF-7 breast cancer cells to determine whether synergistic cancer cell killing effects were observed...
  31. ncbi Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model
    Matthew P Goetz
    Department of Oncology Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:376-84. 2004
    ..Additionally, we discuss some of the ways in which physicians are currently applying this knowledge in the treatment of patients with cancer...
  32. ncbi Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer
    Sejal S Shah
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Hum Pathol 41:103-6. 2010
    ..Clinical studies are needed to determine whether the updated guidelines are better at predicting response to anti-human epidermal growth factor receptor 2 therapy...
  33. ncbi Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score
    Arif H Kamal
    Division of Medical Oncology, Duke Comprehensive Cancer Center, Durham, North Carolina, USA
    Oncologist 16:1359-66. 2011
    ..Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit. We explored the ability of oncologists to predict the RS using standard prognostic criteria...
  34. ncbi A hot flash on tamoxifen metabolism
    Matthew P Goetz
    J Natl Cancer Inst 95:1734-5. 2003
  35. ncbi Gene-expression-based predictors for breast cancer
    Matthew P Goetz
    N Engl J Med 356:752; author reply 752-3. 2007
  36. ncbi Early discontinuation of tamoxifen: a lesson for oncologists
    Matthew P Goetz
    Cancer 110:2595-6; author reply 2596. 2007
  37. ncbi Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series
    Aditya Bardia
    J Clin Oncol 24:e18-9. 2006

Research Grants3

  1. Tamoxifen biotransformation pathway pharmacogenomics
    Matthew Goetz; Fiscal Year: 2009
    ....
  2. Tamoxifen biotransformation pathway pharmacogenomics
    MATTHEW PHILIP GOETZ; Fiscal Year: 2010
    ....